Insulin glulisine

Insulin glulisine
PDB: 6gv0​
Names
Trade namesApidra, Apidra SoloStar
Clinical data
Drug classInsulin (rapid acting)[1]
Main usesType 1 and type 2 diabetes[1]
Side effectsLow blood sugar, pain at the site of injection[2][1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: B3[3]
  • US: C (Risk not ruled out)[3]
    Routes of
    use    		Subcutaneous, intravenous
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa607033
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only [4]
    • EU: Rx-only [2]
    Chemical and physical data
    FormulaC258H384N64O78S6
    Molar mass5822.64 g·mol−1

    Insulin glulisine, sold under the brand name Apidra, is a rapid acting insulin used to treat type 1 and type 2 diabetes.[1] It is given by injection under the skin between 15 minutes before to 20 minutes after starting a meal.[1] It may also be used by injection into a vein.[4] It is generally used with a long acting insulin.[1]

    Common side effects include low blood sugar and pain at the site of injection.[2][1] Other side effects may include allergic reactions, low potassium, and lipodystrophy.[1] It is made by recombinant DNA techniques.[2]

    Insulin glulisine was approved for medical use in the United States and Europe in 2004.[1][2] In the United Kingdom 300 units costs the NHS about £6 as of 2021.[5] In the United States this amount costs just over 100 USD.[6]

    Medical uses

    Insulin glulisine is indicated for the treatment of diabetes mellitus.[2][4]

    Dosage

    The typical dose of all insulins in type 1 DM is 0.2 to 1 unit/kg per day.[1]

    Chemistry

    It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[7]

    History

    It was developed by Sanofi-Aventis.[8]

    References

    1. 1 2 3 4 5 6 7 8 9 10 "Insulin Glulisine Monograph for Professionals". Drugs.com. Archived from the original on 8 August 2020. Retrieved 26 November 2021.
    2. 1 2 3 4 5 6 "Apidra EPAR". European Medicines Agency (EMA). Archived from the original on 10 October 2020. Retrieved 7 October 2020.
    3. 1 2 "Insulin glulisine Use During Pregnancy". Drugs.com. 6 April 2020. Archived from the original on 4 December 2020. Retrieved 21 September 2020.
    4. 1 2 3 "Apidra- insulin glulisine injection, solution Apidra SoloStar- insulin glulisine injection, solution". DailyMed. 6 December 2019. Archived from the original on 25 March 2021. Retrieved 21 September 2020.
    5. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 754. ISBN 978-0857114105.
    6. ↑ "Apidra Prices, Coupons & Savings Tips". GoodRx. Archived from the original on 11 December 2021. Retrieved 26 November 2021.
    7. ↑ "Apidra (insulin glulisine) injection, solution". DailyMed. Archived from the original on 2010-06-15. Retrieved 2020-12-02.
    8. ↑ Jasek W, ed. (2007). Austria-Codex (in Deutsch) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
    Identifiers:
    • "Insulin glulisine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-10-24. Retrieved 2020-12-02.
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.